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The 4q deletion syndrome shows a broad spectrum of clinical manifestations consisting of key features comprising
growth failure, developmental delay, craniofacial dysmorphism, digital anomalies, and cardiac and skeletal defects.
We have identified a de novo interstitial distal deletion in a 9 month-old girl with growth failure, developmental
delay, ventricular septum defect in the subaortic region, patent foramen ovale and patent ductus arteriosus, vascular
malformation of the lung, dysgenesis of the corpus callosum and craniofacial dysmorphism using array-comparative
genomic hybridization. This de novo deletion is located at 4q28.3-31.23 (136,127,048 - 150,690,325), its size is 14.56 Mb,
and contains 8 relevant genes (PCDH18, SETD7, ELMOD2, IL15, GAB1, HHIP, SMAD1, NR3C2) with possible contributions
to the phenotype. Among other functions, a role in lung morphogenesis and tubulogenesis can be attributed to the
deleted genes in our patient, which may explain the unique feature of vascular malformation of the lung leading to
pulmonary hypertension. With the detailed molecular characterization of our case with 4q- syndrome we hope to
contribute to the elucidation of the genetic spectrum of this disorder.
Keywords: 4q28.3-31.23, Array CGH, Deletion, Complex malformation syndrome, Developmental delay, Pulmonary
hypertension, Face dysmorphia, Vascular malformation of the lungBackground
It has now been accepted in the literature that the 4q-
syndrome comprises interstitial and terminal deletions of
the long arm of chromosome 4 [1,2]. Essential features
of this syndrome include mild craniofacial and digital
dysmorphism, developmental delay, growth retardation,
skeletal and cardiac anomalies, and autism spectrum
disorder [2]. A broad spectrum of clinical manifesta-
tions has been observed partly due to the variability in
the extent of the deletions and the possible additional
contribution of other genetic rearrangements, such as
unbalanced translocations [3]. Many reports of 4q- cases
associated with large deletions could be detected by
conventional chromosome analysis; however, in recent* Correspondence: melegh.bela@pte.hu
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unless otherwise stated.years the reports of submicroscopic chromosomal aberra-
tions associated with 4q- phenotype increased as a result
of the widespread diagnostic use of array comparative
genomic hybridization (a-CGH) [3].
A classification of the 4q- deletions has been proposed
by Strehle et al. based on the observation that deletions
appear to occur in clusters along 4q [2]. As demonstrated
in previous case reports, it is not uncommon that array
CGH testing refines or corrects standard karyotyping. We
present the case of a 9-month-old girl with a 14.56 Mb
distal interstitial deletion of chromosome 4, more specific-
ally in the region of 4q28.3-31.23. Reports of distal 4q
interstitial deletions are quite rare. In addition to the key
features seen in 4q- cases epilepsy, small kidneys, hypona-
traemia, immunodeficiency and vascular anomaly of the
lung vessels was also seen in our patient. There had been
limited clinical phenotype and molecular correlation for
congenital heart defects (CHDs) for this region until the
routine use of aCGH, however, in a recent report of a
child with a 4q32.3-q34.3 (chr4:167236114–178816031;td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(15-hydroxyprostaglandin dehydrogenase), and HAND2
(Heart and neural crest derivatives-expressed protein 2)
genes, that are known to be involved in cardiac morpho-
genesis, the critical region responsible for CHDs seen in
4q deletion syndrome was narrowed down [4]. CHDs
are reported to occur in about 60% of patients with 4q
deletion syndrome in the presence or absence of HAND2
deletion, implying additional genes in 4q that could influ-
ence cardiac development. We discuss the possible role of
eight deleted genes in the expression of the unique pheno-
type including the anomaly of the lung vessels seen in our
patient. The precise molecular characterization of new
cases with 4q- syndrome will aid to elucidate the genetic
spectrum of this disorder.
Case presentation
Patient
The index patient was born as the first child to non-
consanguineous healthy parents at 39th week of gestation,
with a birth weight of 2160 g by caesarean section, Apgar
scores were 8/9. Because of heart murmur cardiologic
examination was performed which revealed ventricular
septum defect in the subaortic region, Patent Foramen
Ovale and patent ductus arteriosus. Abdominal ultra-
sound showed smaller kidneys with normal structure
and cranial ultrasound showed dysgenesis of the corpus
callosum.
At the age of two month she was hospitalized due to
feeding problems and hypoglycaemia (blood glucose
value: 1,2 mmol/L). Severe dystrophy, muscle hypotonia
and dysmorphic facial features including remarkable
asymmetry of the face (hemihypertrophy of the left side),
short right palpebral fissure, long eyelashes, asymmetry
of the ears with a dysplastic, smaller and low-set right
ear, short philtrum and high palate were detected. Dur-
ing hospitalization impairment of consciousness and
short atonic periods were present, which were presumed
to be convulsion equivalent, but the performed EEG did
not indicate paroxysmal signs.
At the age of 3 months her congenital heart defect
required surgical correction (closure of the ventricular
septum defect, foramen ovale and ductus arteriosus).
The results of laboratory tests showed no abnormality
besides hyponatremia. After the heart operation there
were no residual defects, the pulmonary pressure was
normal. During the 4th week of the postoperative period,
a severe septic state developed. Because of an advanced
AV-block a temporary pacemaker was needed. She was
dismissed from the hospital and was regularly checked
on by an outpatient cardiology clinic.
Four months following heart surgery she was admitted
to the clinic again because of pulmonary hypertension.
Radiological examinations (Computed Tomography (CT)and CT-angiography) were performed in order to exclude
a possible pulmonary cause which revealed a lower arbor-
isation of the pulmonary arteries supplying the left lower
lobe. No branches were detected to the left upper lobe
and a congenital anomaly was suggested, not excluding
the possibility of a persistent non-recanalized thrombosis.
Cardiomegaly was reported (primarily to the right part of
the heart) with an enlarged pulmonary trunk as a result of
elevated pulmonary arterial pressure. A left sided vena
cava superior and also an atypically localized (left side)
undefined venous vessel was present on the axial and the
reconstructed CT slices. The vena cava inferior and also
the hepatic veins were enlarged due to elevated venous
pressure in the major blood circle. In the thorax cavity
hydrothorax was found on the right side with consolida-
tion on both sides and no normal lung parenchyma.
The severe recurrent infections raised the possibility
of an immunodeficiency, which was confirmed by flow
cytometry of the white blood cells in which significantly
decreased lymphocytes were detected. Although hypo-
calcaemic episodes and high parathyroid hormone levels
were reported in the neonatal period, microdeletion of the
DiGeorge region of chromosome 22 was excluded. Gener-
alized oedema, deterioration of right ventricular function
and recurrent infections progressed, the patient needed
continuous mechanical ventilation and despite therapy
died at the age of nine month.
In search of metabolic diseases urine organic acids,
serum amino acids, ammonia and serum transferrin iso-
electric focusing were performed to exclude congenital
disorders of glycosylation, but all yielded normal results.
Routine karyotyping revealed no visible chromosomal
aberration and Fluorescence In Situ Hybridization (FISH)
analysis of the DiGeorge syndrome critical region (22q11.2)
gave also a normal result (Figure 1).
Methods
Array CGH was performed using the Agilent Human
Genome G3 Sureprint 8x60K Microarray (Agilent Tech-
nologies, Stewens Creek Bld., Santa Clara, CA, 95051
USA), a high resolution 60-mer oligonucleotide based
microarray containing 55,077 60-mer probes, spanning
coding and non-coding genomic sequences with median
spacing of 33 kb and 41 kb, respectively.
Array image was acquired using an Agilent laser scanner
G2565CA (Agilent Technologies, California, USA) and
analyzed with the Agilent Feature Extraction software
(v10.10.1.1.). Results were presented by Agilent Cytoge-
nomics software (v2.5.8.11). DNA sequence information
refers to the public UCSC database (Human Genome
Browser, Feb 2009 Assembly; GRCh37:hg19).
The deletion detected was aligned to known aberrations
listed in publicly available databases, such as the Database
of Chromosomal Imbalance and Phenotype in Humans
Figure 1 Patient’s G-banded karyogram. The banding resolution in this case remained about 400 bphs (bands per haploid set) which is below
the minimum G-banding quality required for analysis of postnatal samples of patients with intellectual disability and/or dysmorphic features
(550 bphs).
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base of Genomic Variants (DGV [6]), Ensembl [7] and
European Cytogeneticists Association Register of Unbal-
anced Chromosome Aberrations (ECARUCA [8]).
Parental samples were analyzed using the same array.
Results and discussion
Array CGH analysis of our patient with complex malforma-
tions revealed a 14.56 Mb deletion on the long arm of
chromosome 4 (4q28.3q31.23; 136,127,048 - 150,690,325)
(see Figure 2). Analysis of the parents confirmed the de
novo occurrence of the deletion. In a detailed analysis of
the genes affected by the deletion we highlighted 8 genes
(PCDH18, SETD7, ELMOD2, IL15, GAB1, HHIP, SMAD1,
NR3C2) with possible contributions to the phenotype. The
genes thought to be relevant are summarized in Table 1 in
order of their position on the chromosome.
The first of these genes is PCDH18 (MIM *608287).
Kasnauskiene J. et al. reported a boy with severe devel-
opmental delay, seizures, microcephaly and hypoplastic
corpus callosum with a 1.53 Mb single gene deletion on
chromosome 4 (4q28.3; 137,417,338 – 138,947,282) with
array CGH. Deletion of the PCDH18 gene was also
detected which together with our case suggests that the
PCDH18 gene might be involved in intellectual disability
[10]. Unfortunately our patient died at the age of nine
months, she was hospitalized many times and showed
severe developmental delay, however we have no data
about her exact intellectual ability, but it is a repeatedly
described symptom in previous reports on 4q interstitialdeletions where the region partially overlaps with ours.
SETD7 (*606594) gene could be a second candidate in
connection with cognitive development. Wang et al.
examined the expression of genes responsible for epi-
genetic changes in different neuronal tissues, especially
during differentiation. It was determined that SETD7
expression was upregulated both in human embryonic
stem cells and human cortex, which implies that SETD7
might play a particular role in the regulation of the
neural genes [11].
The laboratory results of our patient showed decreased
lymphocyte numbers which may be responsible for the
patient’s immunodeficiency. Another gene of the deleted
region is the IL15 (*600554) (see Table 1). Ku et al. sug-
gested earlier that the balance between IL15 and IL2
can control the number of the CD8+ memory T-cells.
Dosage alteration of this gene may explain our patient’s
low lymphocyte number [13].
The clinical picture of our patient was complicated by
vascular lung malformation affecting both the pulmonary
arteries and veins and consequent pulmonary hypertension.
The GAB1 (*604439) gene, which encodes an adaptor
protein and is involved in branching tubulogenesis [14,15]
may also be associated with the vascular malformation of
the lung observed in our patient.
The HHIP (*606178) gene encodes a protein which
participates in the regulation of morphogenesis. Zhou et al.
found decreased levels of HHIP mRNA and protein in the
lung tissue samples of COPD patients. Based on these, a
possible correlation between the abnormal development of
Figure 2 Ensembl and aCGH image of the deleted region with the affected genes. Part B is our aCGH image where the deleted region is
clearly visible and its location on chromosome 4 is marked. Listed on the right side are all of the genes affected by this deletion. The first eight are
emphasized because these are most likely to affect the phenotype. Part A is the Ensembl image of this area with the affected genes highlighted [9].
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excluded [16,17].
The unique feature of vascular malformation in the
lung, gradually lead to pulmonary hypertension in our
patient. Additionally the role of genes in the deleted
region associated with the development of pulmonary
hypertension cannot be ruled out. Han et al., examined
the SMAD1 (*601595) gene (in knock-out mice), and
found that the deficiency of it is associated with pulmon-
ary hypertension [18]. Pannu et al. noticed the importanceof SMAD1 in the development of fibrosis [19]. In a publi-
cation by Nasim et al. the same results were discovered
when they examined a 47-year-old French woman with
primary pulmonary hypertension [20]. Furthermore, muta-
tions in ELMOD2 (*610196) gene (deleted in our patient)
may lead to familial idiopathic pulmonary fibrosis [12],
however in our patient we have no data about parenchymal
changes of the lung.
Another gene affected by this deletion with possible
effect on the phenotype, called NR3C2, plays a role in
Table 1 Deleted genes on the long arm of the chromosome 4, with a possible effect on the phenotype
GENES WITH POSSIBLE EFFECT ON THE PHENOTYPE
Gene Role Position on chr 4 Effect on the phenotype
PCDH18 Protocadherin 18: impact on cell-cell connection,
highly expressed in the brain and lung.
138,440,071 Might be involved in intellectual disability [10].
-
138,453,628
SETD7 Histone methyltransferase H3K4. 140,427,191 Regulation of the neural genes; differentiation
of neuroectoderm progenitor cells [11].
-
140,477,576
ELMOD2 GTPase activating protein: role in antiviral responses
and pulmonary fibrosis.




IL15 Cytokine:affects T-cell activation and proliferation,
controls the number of CD8+ memory T cells.
142,557,748 Dosage alteration of IL15 gene may explain patient’s
low lymphocyte number [13].
-
142,655,139
GAB1 Direct substrate of the epidermal growth factor receptor (EGFR). 144,257,679 Has an important role in branching tubulogenesis,
and probably in the lung vessel malformation
observed in our patient [14,15].-
144,359,717
HHIP Hedgehog-Interacting Protein: effect on regulation
of morphogenesis.
145,567,417 Possible correlation between the lung malformation
of our patient and the gene [16,17].
-
145,662,541
SMAD1 Involved in the downstream signaling pathway of bone
morphogenic protein (BMP) subfamily members.
146,402,950 SMAD1 deficiency may play a role in the
development of pulmonary hypertension [18-20].
-
146,480,327
NR3C2 Mineralocorticoid receptor: impact on the regulation of sodium
concentration in the body. NR3C2 mutations were published to
influence the development of hyponatraemia.
148,999,914 Copy number changes of NR3C2 gene may be
associated with low sodium levels [21].
-
149,365,849
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influencing fluidic balance and blood pressure. We cannot
rule out the possibility that changes in copy number of
this gene may be associated with low sodium levels conse-
quently seen in our patient [21].Conclusion
Several genes are affected in the deletion of the region
between 4q28.3 and 4q31.23, which could give a possible
explanation for the clinical symptoms. Among other func-
tions a role in lung morphogenesis and tubulogenesis can
be attributed to the deleted genes in our patient which
may explain the unique feature of vascular malformation
of the lung vessels leading to pulmonary hypertension.
The interpretation of the role of the haploinsufficient
genes is complicated by the fact that in current literature
we only found a few cases where the deletion overlapped
our region. In the future it would be necessary to examine
this region not only with array CGH but also with tran-
scriptomic and proteomic methods.Consent
Because the patient died, written consent for publication
and any accompanying images in this Case report was
obtained from the patient’s next of kin. A copy of the
written consent is available for review by the Editor-in-
Chief of this journal.
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